Propanc Biopharma, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PPCB | PCSA | PMCB | NCNA | ALLR | TPST | |
|---|---|---|---|---|---|---|
| Market cap | 1.85M | 5.41M | 4.09M | 4.25M | 17.18M | 9.26M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -0.5 | -1.0 | -0.1 | -1.3 | -0.4 |
| Price/book | 0.1 | -17.0 | 0.1 | 0.2 | 4.9 | -6.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −99.42% | −77.18% | −61.58% | −73.68% | −7.38% | −95.29% |
| Today | +4.68% | −0.26% | +12.03% | +0.99% | −4.42% | −1.13% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PPCB news ›Propanc Biopharma announces 1-for-10 reverse stock split
Propanc Biopharma (PPCB) announced that its board of directors, approved a 1-for-10 reverse stock split of the company’s issued and outstanding ... Propanc Biopharma announces 1-for-10 reverse stock split Propanc Biopharma (PPCB) announced…
Propanc Biopharma announces new PRP preclinical data
Propanc Biopharma (PPCB) announced new preclinical data supporting the potential of its lead asset, PRP, to address chemotherapy resistance in p... Propanc Biopharma announces new PRP preclinical data Propanc Biopharma (PPCB) announced new…
Propanc Biopharma targets February start for first-in-human cancer study
Propanc Biopharma (PPCB) announced it is advancing its clinical development program for PRP, its investigational proenzyme-based therapeutic can... Propanc Biopharma targets February start for first-in-human cancer study Propanc Biopharma…
Metformin and valproic acid combo strips cancer cells of chemo tolerance
That metabolic shift came with functional consequences. The persister cells produced more ATP, the cell’s energy currency, and mounted stronger antioxidant survival responses, helping them withstand the oxidative and drug-induced stress of…
Editorial: Mechanisms of drug resistance in cancer: overcoming barriers with novel pharmacological strategies
An editorial summarizing eight contributions describes cancer drug resistance as an adaptive process involving genetic, epigenetic, metabolic, signalling and microenvironmental mechanisms, while identifying preclinical and computational…
Tubocapsenolide A Disrupts PLK1-Linked Damage Clearance in Oxaliplatin-Resistant Colorectal Cancer
A preclinical study finds that tubocapsenolide A inhibits PLK1, disrupting ESCRT-mediated damage clearance and restoring oxaliplatin sensitivity in resistant colorectal cancer models. The mechanism connects PLK1 with the endosomal sorting…
Propanc Biopharma Reports Preclinical Data Showing PRP May Help Reverse Chemotherapy Resistance in Pancreatic Cancer
Propanc Biopharma is focused on developing novel treatments for chronic diseases, particularly recurrent and metastatic cancer. The study investigates PRP as a potential strategy to overcome chemotherapy resistance in pancreatic cancer.…
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
The findings span intravenous treatment in cancer models and survival observations in patients receiving a rectal proenzyme formulation. Propanc Biopharma (PPCB) announced publication of a peer-reviewed pilot study evaluating PRP in…
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
Propanc plans to move PRP into a first-in-human study expected to enroll up to 50 patients with advanced solid tumors. Propanc Biopharma (PPCB) reported preclinical pancreatic cancer results for PRP, including more than 90% mean tumor…
Clinical Update from the Ongoing Phase 2 Trial of PRV111, the First Non-Surgical Therapy in Development for Early-Stage Oral Cancer
Oct 05, 2026, 10:00 ET The CLN-004 study builds upon Privo's earlier clinical experience with PRV111 (CLN-001), which showed promising local tumor responses with no systemic toxicity in a first-in-human setting. The results of that earlier…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com10
- stocktitan.net3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.